The DEPSTER project, entirely initiated and piloted by MAPREG, was designed to bring revolution to the treatment of Depressive Disorders. It was ranked 6th at the European level and was awarded an EUREKA / EUROSTARS grant.
Based on its impressive preclinical efficacy and safety, MAP4343 received the european orphan drug status to treat Spinal Cord Injuries, a rare but dreadful situation devoid of any medical solution.
MAPREG investors trust our technology; their support helps us raise grants for each of our developments.
80 Rue du Général Leclerc,
94270 Kremlin Bicêtre